Docket No. ORT1596DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: K. S. TenHuisen et al. Confirmation No.: 1782

Serial No.: 10/602,924 Art Unit: 3736

Filed: June 24, 2003 Examiner:

For : Method of Modulating the Immune System in an

Animal to an Antigen

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

William K. Wissing
(Name of applicant, assignee, or Registered Representative)

119-2

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on June 24, 2003.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97 1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.

☐ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with ☐ the

∐ In ac	ccordance w	vith §	1.129	(a), t	his Inf	formation	n
Disclosure Stat	ement is b	eing	filed	in co	nnectio	on with [] the
first or 🗌 seco	nd After F	inal	Submis	sion,	theref	ore:	
	Statement	in Ac	ccordar	nce wi	th §1.9	97(e)	
	(attached)	; or					
	Please cha	arge I	Deposit	Acco	ount No	. 10-	
	0750/	/	the fe	ee of	\$180.00	as set	forth
	in §1.17(p	p).					

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
oxtimes Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Coning of only foreign nations decuments and way
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not
enclosed because this U.S. patent application was filed after
June 30, 2003 or this international application has entered the
national stage under 35 USC §371 after June 30, 2003 (see USPTO
waiver of requirement under 37 CFR 1.98 (a)(2)(i).
oxtimes There are no listed references which are not in the
English language.
The relevance of those listed references which are
not in the English language is as follows:

	Attached	are cop	pies d	of sea	rch rep	port	(s) from	n	
correspon	nding pater	nt appli	icatio	on(s),	which	are	listed	on	the
attached	Submission	Under	MPEP	609 D	•				
			_	_				_	

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1596DIV/WKW. This form is submitted in triplicate.

Respectfully submitted,

William K. Wissing

Reg. No. 34,757

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003

(732) 524-6201 DATED: 62/25/65 der the Peperwark Reduction Act of 1995, no persons are required to respond to a collection of information unless, tidisc also also a CMB control numb

c.	bstltut		4-621	4 4 4 0 4	DTA
-	meririir	ល ពេក	TOTAL/	144:14	P 1 U
		• •••	. 4.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

ا الله الله المن المن المن المن المن المن المن المن	assitus, a te d'und te l'elle
Confirmation Number	1782
Application Number	10/602,924
Filing Date	06/24/2003
First Named Inventor	K. S. TenHuisen
Group Art Unit	3736
Examiner Name	
Attorney Docket Number	ORT1596DIV

[[U.S. Patent Ducument		U.S. PATENT DOCUMENTS		Υ
Exam. Init als	Cito No 1	Number	Kind Code ² (if known)	Name of Patenteo or Applicant of Cited Document	Date of Publication of Cited Decument mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant I gures appear
		4,128,612	А	Roth	12-05-1978	
		5,676,943	Α	Baetge et al.	10-14-1997	
		6,031,148	Α	Hayes et al.	02-29-2000	
		6,200,589	B1	Kennedy et al.	03-13-2001	
		6,303,136	B1	Li et al.	10-16-2001	
		6,334,968	B1	Shapiro et al.	01-01-2002	
		6,551,355	B1	Lewandrowski et al.	04-22-2003	
		2003/0118630	A1	Cerami et al.	06-26-2003	

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Pages, Columns, Publication of Lines, where relevant Name of Patentee or Cited Document passages or relevant Exam Cite ,6 Applicant of Cited Document figures appear initials Number¹ KindCode⁵ mm-dd-yyyy Office³ No.1 12-26-1991 WO A1 E.I. Du Pont de Nemours 91/19464

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²					
		1					
		 					
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					

Examiner	Daie	
Signature	Considered	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.